Neuroprotection Mediated by BDNF and its Recombinant Isoforms in Neuron-Like Cells Exposed to Glutamatergic Hyperexcitability

• Grant number: 25/06653-3
• Support Opportunities: Scholarships in Brazil - Scientific Initiation
• Start date: August 01, 2025
• End date: July 31, 2026
• Field of knowledge: Biological Sciences - Pharmacology - Biochemical and Molecular Pharmacology
• Principal Investigator: Renê de Oliveira Beleboni
• Grantee: Marcus Vinicius Pomini
• Host Institution: Universidade de Ribeirão Preto (UNAERP). Campus Ribeirão Preto. Ribeirão Preto , SP, Brazil
• Associated research grant: 23/05079-6 - Production, structural and functional validation of the BDNF neurotrophin and its recombinant proisoforms with emphasis in depressive disorder, AP.R

Abstract

BDNF (Brain Derived Neurotrophic Factor) is an essential neurotrophin for synaptic plasticity, neurogenesis, and neuronal survival, and its regulation is a promising approach to mitigate neural damage associated with neuropathological conditions such as depression, schizophrenia, epilepsy, and different neurodegenerative diseases. Indeed, this project aims to investigate the role of BDNF and its main recombinant isoforms in the differentiation of neuron-like cells challenged by excitotoxicity and their potential neuroprotective effects against oxidative stress. Using the PC-12 cell line, differentiated into neuron-like cells, the study will evaluate morphological parameters, expression of neuronal biomarkers, and cytokine production through in vitro biochemical assays, such as quantification of reactive oxygen species (ROS) and cell viability to determine the potential protective effects of BDNF and/or its recombinant isoforms. It is hoped that the results will confirm the efficacy of BDNF and/or its isoforms in promoting neuroprotection, demonstrating their ability to reduce oxidative damage and preserve neuronal integrity, as well as expanding scientific knowledge surrounding the interactions between these neurotrophins and neuronal damage frequently associated with diseases. Our findings could contribute to the development of new therapeutic approaches, especially for neurodegenerative diseases and psychiatric disorders, as well as identifying potential biomarkers of response to treatment. (AU)